Trikafta (elexacaftor/tezacaftor/ivacaftor) - Vertex
Impact of Trikafta on P2X7R and Clinical Outcomes in Cystic Fibrosis (clinicaltrials.gov) - Sep 26, 2026 - P=N/A | N=35 | Completed | Sponsor: Ain Shams University 
New trial • Cystic Fibrosis • Genetic Disorders • Immunology • Pulmonary Disease • Respiratory Diseases
http://clinicaltrials.gov/ct2/show/NCT07841353
 
Sep 26, 2026
 
Prev Next